Novel antiplatelet targets in the treatment of acute coronary syndromes

References

• Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1–25. Epub 2017/ 05/17.
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep 2015;7:8.
   PubMedGoogle Scholar
• Torpy JM, Burke AE, Glass RM. Acute Coronary Syndromes. JAMA 2010;303:90.
   PubMed Web of Science ®Google Scholar
• Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004;61:498–511.
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227–1234.
   PubMed Web of Science ®Google Scholar
• Tomaiuolo M, Brass LF, Stalker TJ. Regulation of platelet activation and coagulation and its role in vascular injury and arterial thrombosis. Interv Cardiol Clin 2017;6:1–12.
   PubMedGoogle Scholar
• Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci USA 2002;99:425.
   PubMed Web of Science ®Google Scholar
• Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn ML. GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood 2005;106:1268–1277. Epub 2005/ 05/10.
   PubMed Web of Science ®Google Scholar
• Lecut C, Schoolmeester A, Kuijpers MJ, Broers JL, van Zandvoort MA, Vanhoorelbeke K, Deckmyn H, Jandrot-Perrus M, Heemskerk JW. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004;24:1727–1733. Epub 2004/ 07/03.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Mihara K, Thibeault P, Vanderboor CM, Petri B, Saifeddine M, Bouvier M, Hollenberg MD. Targeting a proteinase-activated receptor 4 (PAR4) carboxyl terminal motif to regulate platelet function. Mol Pharmacol 2017;91:287–295. Epub 2017/ 01/28.
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004;10:171–178.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment ELEVATIon of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. Epub 2015/ 09/01.
   PubMed Web of Science ®Google Scholar
• Levine Glenn N, Bates Eric R, Bittl John A, Brindis Ralph G, Fihn Stephan D, Fleisher Lee A, Granger Christopher B, Lange Richard A, Mack Michael J, Mauri L, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with Non–ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 2016;134:e123–e155.
   PubMed Web of Science ®Google Scholar
• Said SM, Hahn J, Schleyer E, Muller M, Fiedler GM, Buerke M, Prondzinsky R. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol 2007;96:61–69. Epub 2006/ 12/06.
   PubMed Web of Science ®Google Scholar
• Wadowski PP, Pultar J, Weikert C, Eichelberger B, Panzer B, Huber K, Lang IM, Koppensteiner R, Panzer S, Gremmel T. Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y(12) inhibitors. Res Pract Thrombosis Haemostasis 2019;3:383–390.
   PubMed Web of Science ®Google Scholar
• Pasalic L, Wing-Lun E, Lau JK, Campbell H, Pennings GJ, Lau E, Connor D, HP L, Muller D, Kritharides L, et al. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J Thrombosis Haemostasis 2018;16:1198–1210. Epub 2018/ 05/08.
   PubMed Web of Science ®Google Scholar
• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349–360. Epub 1988/ 08/13.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502. Epub 2001/ 08/25.
   PubMed Web of Science ®Google Scholar
• Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol 2000;23(Suppl 6):Vi-3-7. Epub 2000/ 12/29.
   PubMedGoogle Scholar
• Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006;108:936–942. Epub 2006/ 07/25.
   PubMed Web of Science ®Google Scholar
• Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997;272:23528–23531. Epub 1997/ 09/20.
   PubMed Web of Science ®Google Scholar
• Alshehri OM, Hughes CE, Montague S, Watson SK, Frampton J, Bender M, Watson SP. Fibrin activates GPVI in human and mouse platelets. Blood 2015;126:1601–1608.
   PubMed Web of Science ®Google Scholar
• Mangin PH, Onselaer MB, Receveur N, Le LN, Hardy AT, Wilson C, Sanchez X, Loyau S, Dupuis A, Babar AK, et al. Immobilized fibrinogen activates human platelets through glycoprotein VI. Haematologica 2018;103:898–907. Epub 2018/ 02/24.
   PubMed Web of Science ®Google Scholar
• Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, Schneider S, Besta F, Muller I, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. Faseb J 2004;18:397–399. Epub 2003/ 12/06.
   PubMedGoogle Scholar
• Mojica Munoz AK, Jamasbi J, Uhland K, Degen H, Munch G, Ungerer M, Brandl R, Megens R, Weber C, Lorenz R, et al. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. Thromb Haemost 2017;117:1651–1659. Epub 2017/ 06/02.
   PubMed Web of Science ®Google Scholar
• Schonberger T, Ziegler M, Borst O, Konrad I, Nieswandt B, Massberg S, Ochmann C, Jurgens T, Seizer P, Langer H, et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Am J Physiol Cell Physiol 2012;303:C757–766. Epub 2012/ 07/21.
   PubMed Web of Science ®Google Scholar
• Schonberger T, Siegel-Axel D, Bussl R, Richter S, Judenhofer MS, Haubner R, Reischl G, Klingel K, Munch G, Seizer P, et al. The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice. Cardiovasc Res 2008;80:131–137. Epub 2008/ 06/21.
   PubMed Web of Science ®Google Scholar
• Ungerer M, Li Z, Baumgartner C, Goebel S, Vogelmann J, Holthoff HP, Gawaz M, Munch G. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS One 2013;8:e71193. Epub 2013/ 08/21.
   PubMed Web of Science ®Google Scholar
• Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Munch G. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011;123:1891–1899. Epub 2011/ 04/20.
   PubMed Web of Science ®Google Scholar
• Schupke S, Hein-Rothweiler R, Mayer K, Janisch M, Sibbing D, Ndrepepa G, Hilz R, Laugwitz KL, Bernlochner I, Gschwendtner S, et al. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective PCI-design and rationale of the randomized ISAR-PLASTER trial. Thromb Haemost 2019;119:1539–1545. Epub 2019/ 06/22.
   PubMed Web of Science ®Google Scholar
• Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks. mAbs 2017;9:945–958.
   PubMed Web of Science ®Google Scholar
• Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, et al. Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of\ ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol 2019;39:956–964. Epub 2019/ 04/25.
   PubMed Web of Science ®Google Scholar
• Anil Kumar KS, Misra A, Siddiqi TI, Srivastava S, Jain M, Bhatta RS, Barthwal M, Dikshit M, Dikshit DK. Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. Eur J Med Chem 2014;81:456–472.
   PubMed Web of Science ®Google Scholar
• Misra A, Prakash P, Aggarwal H, Dhankani P, Kumar S, Pandey CP, Pugh N, Bihan D, Barthwal MK, Farndale RW, et al. Anti-thrombotic efficacy of S007-867: pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro. Biochem Pharmacol 2018;148:288–297. Epub 2018/ 01/09.
   PubMed Web of Science ®Google Scholar
• Florian P, Wonerow P, Harder S, Kuczka K, Dubar M, Graff J. Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber. Eur J Clin Pharmacol 2017;73:949–956. Epub 2017/ 05/20.
   PubMed Web of Science ®Google Scholar
• Onselaer M-B, Nagy M, Pallini C, Pike JA, Perrella G, Quintanilla LG, Eble JA, Poulter NS, Heemskerk JWM, Watson SP. Comparison of the GPVI inhibitors losartan and honokiol. Platelets 2020;31:187–197.
   PubMed Web of Science ®Google Scholar
• Chang CH, Chung CH, Tu YS, Tsai CC, Hsu CC, Peng HC, Tseng YJ, Huang TF. Trowaglerix venom polypeptides as a novel antithrombotic agent by targeting immunoglobulin-like domains of glycoprotein VI in platelet. Arterioscler Thromb Vasc Biol 2017;37:1307–1314. Epub 2017/ 06/10.
   PubMed Web of Science ®Google Scholar
• Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, Lecocq JP, Pouyssegur J, Van Obberghen-Schilling E. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991;288:123–128. Epub 1991/ 08/19.
   PubMed Web of Science ®Google Scholar
• Xu W-F, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998;95:6642.
   PubMed Web of Science ®Google Scholar
• Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, Moliterno DJ, Strony J, Van de Werf F, et al. Stroke outcomes with vorapaxar versus placebo in patients with acute coronary syndromes: insights from the TRACER trial. J Am Heart Assoc 2018;7:e009609–e009609.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de WF, White HD, Aylward PE, Wallentin L, Chen E, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20–33. Epub 2011/ 11/15.
   PubMed Web of Science ®Google Scholar
• Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998;95:6642–6646.
   PubMed Web of Science ®Google Scholar
• Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000;275:25216–25221. Epub 2000/ 06/06.
   PubMed Web of Science ®Google Scholar
• Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000;39:5458–5467.
   PubMed Web of Science ®Google Scholar
• Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J, Hamm HE. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. J Biol Chem 2006;281:26665–26674. Epub 2006/ 07/14.
   PubMed Web of Science ®Google Scholar
• Rigg RA, Healy LD, Chu TT, Ngo ATP, Mitrugno A, Zilberman-Rudenko J, Aslan JE, Hinds MT, Vecchiarelli LD, Morgan TK, et al. Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets 2019;30:126–135. Epub 2018/ 12/19.
   PubMed Web of Science ®Google Scholar
• Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 2014;124:3450–3458. Epub 2014/ 10/07.
   PubMed Web of Science ®Google Scholar
• Morikawa Y, Kato H, Kashiwagi H, Nishiura N, Akuta K, Honda S, Kanakura Y, Tomiyama Y. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca(2+) mobilization and ERK phosphorylation in healthy Japanese subjects. Thromb Res 2018;162:44–52. Epub 2018/ 01/01.
   PubMed Web of Science ®Google Scholar
• Norman JE, Cunningham MR, Jones ML, Walker ME, Westbury SK, Sessions RB, Mundell SJ, Mumford AD. Protease-activated receptor 4 variant p.Tyr157Cys reduces platelet functional responses and alters receptor trafficking. Arterioscler Thromb Vasc Biol 2016;36:952–960. Epub 2016/ 03/12.
   PubMed Web of Science ®Google Scholar
• French SL, Thalmann C, Bray PF, Macdonald LE, Murphy AJ, Sleeman MW, Hamilton JR. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. Blood Adv 2018;2:1283–1293. Epub 2018/ 06/10.
   PubMed Web of Science ®Google Scholar
• Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017;9: Epub 2017/ 01/06.
   Web of Science ®Google Scholar
• Wilson Simon J, Ismat Fraz A, Wang Z, Cerra M, Narayan H, Raftis J, Gray Timothy J, Connell S, Garonzik S, Ma X, et al. PAR4 (Protease-Activated Receptor 4) antagonism with BMS-986120 Inhibits human Ex Vivo thrombus formation. Arterioscler Thromb Vasc Biol 2018;38:448–456.
   PubMed Web of Science ®Google Scholar
• Wong Pancras C, Watson Carol A, Bostwick J, Banville J, Wexler Ruth R, Priestley ES, Marinier A, Bouvier M, Gordon D, Schumacher W, et al. Abstract 13794: an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, prevents aeterial thrombosis with low bleeding liability in cynomolgus monkeys. Circulation 2017;136:A13794–A13794.
   Web of Science ®Google Scholar
• Identifier NCT02341638,single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-986141 in healthy subjects. 2017 Mar 31. Available from: https://clinicaltrials.gov/ct2/show/NCT02341638
   Google Scholar
• Identifier NCT02671461, safety and efficacy study of a protease activated receptor-4 antagonist being tested to reduce the chances of having additional strokes or “Mini strokes”. ClinicalTrials.gov Registry; 2019 Dec 12 [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02671461
   Google Scholar
• Reganon E, Vila V, Martinez-Sales V, Vaya A, Aznar J. Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction. Haematologica 2002;87:740–745. discussion 745. Epub 2002/ 07/02.
   PubMed Web of Science ®Google Scholar
• Du X, Beutler L, Ruan C, Castaldi PA, Berndt MC. Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. Blood 1987;69:1524–1527. Epub 1987/ 05/01.
   PubMed Web of Science ®Google Scholar
• Modderman PW, Admiraal LG, Sonnenberg A, von Dem Borne AE. Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J Biol Chem 1992;267:364–369. Epub 1992/ 01/05.
   PubMed Web of Science ®Google Scholar
• Andrews RK, Berndt MC. Bernard-Soulier syndrome: an update. Semin Thromb Hemost 2013;39:656–662. Epub 2013/ 08/10.
   PubMed Web of Science ®Google Scholar
• Uff S, Clemetson JM, Harrison T, Clemetson KJ, Emsley J. Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem 2002;277:35657–35663. Epub 2002/ 06/28.
   PubMed Web of Science ®Google Scholar
• De ML, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha. J Biol Chem 1994;269:6478–6484. Epub 1994/ 03/04.
   PubMed Web of Science ®Google Scholar
• Romo GM, Dong J-F, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, López JA. The Glycoprotein Ib-IX-V Complex Is a Platelet Counterreceptor for P-Selectin. J Exp Med 1999;190:803.
   PubMed Web of Science ®Google Scholar
• ALX-0081-2.1_09 - CSR synopsis for disclosure - final [Report]. The European Union clinical trials register website: ablynx; 2019 Dec 11. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012206-39/results
   Google Scholar
• Duggan S. Caplacizumab: first global approval. Drugs 2018;78:1639–1642. Epub 2018/ 10/10.
   PubMed Web of Science ®Google Scholar
• Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678–2686. Epub 2007/ 11/21.
   PubMed Web of Science ®Google Scholar
• Markus Hugh S, McCollum C, Imray C, Goulder Michael A, Gilbert J, King A. The von willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy. Stroke 2011;42:2149–2153.
   PubMed Web of Science ®Google Scholar
• ISRCTN01837376, Study of ARC1779 in patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI) (vITAL-1); 2008 Aug 08 [cited 2019 Dec 10]. Available from: http://www.isrctn.com/ISRCTN01837376
   Google Scholar
• Siller-Matula Jolanta M, Merhi Y, Tanguay J-F, Duerschmied D, Wagner Denisa D, McGinness Kathleen E, Pendergrast PS, Chung J-K, Tian X, Schaub Robert G, et al. ARC15105 is a potent antagonist of Von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol 2012;32:902–909.
   PubMed Web of Science ®Google Scholar
• Hou Y, Reheman A, Li Benjamin X, Dai X, Yang Z, Qian F, Zhang G, Xu Z, Liu J, Liang C, et al. Abstract 499: development of a novel antithrombotic therapy targeting platelet GPIbα: assessment of anfibatide In Vitro and in phase I clinical trial. Arterioscler Thromb Vasc Biol 2014;34:A499–A499.
   PubMed Web of Science ®Google Scholar
• Lei X, Reheman A, Hou Y, Zhou H, Wang Y, AH M, Liang C, Dai X, Li BX, Vanhoorelbeke K, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014;111:279–289. Epub 2013/ 11/01.
   PubMed Web of Science ®Google Scholar
• Identifier NCT01585259, Anfibatide Phase Ib-IIa clinical trial; 2016 June 03 [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01585259
   Google Scholar
• Ashton J, Benedict C, Fitzgerald C, Raheja S, Taylor A, Campbell W, Buja L, Willerson J. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986;73:572–578.
   PubMed Web of Science ®Google Scholar
• Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997;(8):517–523. Epub 1998/ 03/10.
   PubMed Web of Science ®Google Scholar
• Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord 2012;136:99–103. Epub 2011/ 09/07.
   PubMed Web of Science ®Google Scholar
• Williams MS, Ziegelstein RC, McCann UD, Gould NF, Ashvetiya T, Vaidya D. Platelet serotonin signaling in patients with cardiovascular disease and comorbid depression. Psychosom Med 2019;81:352–362. Epub 2019/ 03/12.
   PubMed Web of Science ®Google Scholar
• Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894–1898. Epub 2001/ 10/17.
   PubMed Web of Science ®Google Scholar
• Noordam R, Aarts N, Leening MJ, Tiemeier H, Franco OH, Hofman A, Stricker BH, Visser LE. Use of antidepressants and the risk of myocardial infarction in middle-aged and older adults: a matched case-control study. Eur J Clin Pharmacol 2016;72:211–218. Epub 2015/ 11/08.
   PubMed Web of Science ®Google Scholar
• Uchiyama S, Ozaki Y, Satoh K, Kondo K, Nishimaru K. Effect of sarpogrelate, a 5-HT2A antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovascular Dis 2007;24:264–270.
   PubMed Web of Science ®Google Scholar
• Noh Y, Lee J, Shin S, Lim HS, Bae SK, Oh E, Kim GJ, Kim JH, Lee S. Antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using the Korean national health insurance claim database. PLoS One 2016;11:e0150475. Epub 2016/ 03/05.
   PubMed Web of Science ®Google Scholar
• Choi JH, Cho JR, Park SM, Shaha KB, Pierres F, Sumiya T, Chun KJ, Kang MK, Choi S, Lee N. Sarpogrelate based triple antiplatelet therapy improved left ventricular systolic function in acute myocardial infarction: retrospective study. Yonsei Med J 2017;58:959–967.
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke 2008;39:1827–1833. Epub 2008/ 04/05.
   PubMed Web of Science ®Google Scholar
• Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991;65:415–420. Epub 1991/ 04/08.
   PubMed Web of Science ®Google Scholar
• Adams JW, Ramirez J, Shi Y, Thomsen W, Frazer J, Morgan M, Edwards JE, Chen W, Teegarden BR, Xiong Y, et al. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther 2009;331:96–103. Epub 2009/ 07/25.
   PubMed Web of Science ®Google Scholar
• Przyklenk K, Frelinger AL 3rd, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2010;8:331–340. Epub 2009/ 11/20.
   PubMed Web of Science ®Google Scholar
• Identifier NCT02419820,randomized, double-blind, placebo-controlled, dose-escalation, repeated and single oral dosing phase i study to assess the pharmacokinetics, pharmacodynamics and safety of temanogrel co-administered with aspirin and clopidogrel; 2019 Feb 15 [cited 2019 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02419820
   Google Scholar
• Lin OA, Karim ZA, Vemana HP, Espinosa EVP, Khasawneh FT. The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. PLoS One 2014;9:e87026–e87026.
   PubMed Web of Science ®Google Scholar
• Moerland M, Kemme M, Dijkmans A, Bergougnan L, Burggraaf J. Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans. J Cardiovasc Pharmacol 2011;58:575–580. Epub 2011/ 08/09.
   PubMed Web of Science ®Google Scholar
• Berry CN, Lorrain J, Lochot S, Delahaye M, Lale A, Savi P, Lechaire I, Ferrari P, Bernat A, Schaeffer P, et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost 2001;85:521–528. Epub 2001/ 04/20.
   PubMed Web of Science ®Google Scholar
• Osler M, Mårtensson S, Wium-Andersen IK, Prescott E, Andersen PK, Jørgensen TSH, Carlsen K, Wium-Andersen MK, Jørgensen MB. Depression after first hospital admission for acute coronary syndrome: a study of time of onset and impact on survival. Am J Epidemiol 2016;183:218–226.
   PubMed Web of Science ®Google Scholar
• Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood 1995;86:2168–2173. Epub 1995/ 09/15.
   PubMed Web of Science ®Google Scholar
• Chen K, Lin Y, Detwiler TC. Protein disulfide isomerase activity is released by activated platelets. Blood 1992;79:2226–2228. Epub 1992/ 05/01.
   PubMed Web of Science ®Google Scholar
• Essex DW, Li M. Protein disulphide isomerase mediates platelet aggregation and secretion. Br J Haematol 1999;104:448–454.
   PubMed Web of Science ®Google Scholar
• Kim K, Hahm E, Li J, Holbrook LM, Sasikumar P, Stanley RG, Ushio-Fukai M, Gibbins JM, Cho J. Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood 2013;122:1052–1061. Epub 2013/ 06/22.
   PubMed Web of Science ®Google Scholar
• Li J, Kim K, Jeong S-Y, Chiu J, Xiong B, Petukhov Pavel A, Dai X, Li X, Andrews Robert K, Du X, et al. Platelet protein disulfide isomerase promotes glycoprotein ibα–mediated platelet-neutrophil interactions under thromboinflammatory conditions. Circulation 2019;139:1300–1319.
   PubMed Web of Science ®Google Scholar
• Severino A, Campioni M, Straino S, Salloum FN, Schmidt N, Herbrand U, Frede S, Toietta G, Di Rocco G, Bussani R, et al. Identification of protein disulfide isomerase as a cardiomyocyte survival factor in ischemic cardiomyopathy. J Am Coll Cardiol 2007;50:1029–1037. Epub 2007/ 09/11.
   PubMed Web of Science ®Google Scholar
• Jasuja R, Passam FH, Kennedy DR, Kim SH, van Hessem L, Lin L, Bowley SR, Joshi SS, Dilks JR, Furie B, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012;122:2104–2113. Epub 2012/ 05/08.
   PubMed Web of Science ®Google Scholar
• Lin L, Gopal S, Sharda A, Passam F, Bowley SR, Stopa J, Xue G, Yuan C, Furie BC, Flaumenhaft R, et al. Quercetin-3-rutinoside inhibits protein disulfide isomerase by binding to Its b’x domain. J Biol Chem 2015;290:23543–23552. Epub 2015/ 08/03.
   PubMed Web of Science ®Google Scholar
• Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight 2017;2:e89373. Epub 2017/ 01/18.
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 2019;4:e125851. Epub 2019/ 01/18.
   PubMed Web of Science ®Google Scholar
• Stainer AR, Sasikumar P, Bye AP, Unsworth AJ, Holbrook LM, Tindall M, Lovegrove JA, Gibbins JM. The metabolites of the dietary flavonoid quercetin possess potent antithrombotic activity, and interact with aspirin to enhance antiplatelet effects. TH Open 2019;3:e244–e258.
   PubMedGoogle Scholar
• Bendapudi PK, Bekendam RH, Lin L, Huang M, Furie B, Flaumenhaft R. ML359, a small molecule inhibitor of protein disulfide isomerase that prevents thrombus formation and inhibits oxidoreductase but not transnitrosylase activity. Blood 2014;124:2880.
   Web of Science ®Google Scholar
• Kung PH, Hsieh PW, Lin YT, Lee JH, Chen IH, Wu CC. HPW-RX40 prevents human platelet activation by attenuating cell surface protein disulfide isomerases. Redox Biol 2017;13:266–277. Epub 2017/ 06/11.
   PubMed Web of Science ®Google Scholar
• McEver RP, Martin M. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Bio Chem 1984;259:9799–9804.
   PubMed Web of Science ®Google Scholar
• Vischer UM, Wagner DD. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood 1993;82:1184–1191.
   PubMed Web of Science ®Google Scholar
• Burns AR, Bowden RA, Abe Y, Walker DC, Simon SI, Entman ML, Smith CW. P-selectin mediates neutrophil adhesion to endothelial cell borders. J Leukoc Biol 1999;65:299–306. Epub 1999/ 03/18.
   PubMed Web of Science ®Google Scholar
• Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000;102:1931–1936.
   PubMed Web of Science ®Google Scholar
• Sarma J, Laan Caterina A, Alam S, Jha A, Fox Keith AA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166–2171.
   PubMed Web of Science ®Google Scholar
• Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61–67.
   PubMed Web of Science ®Google Scholar
• Oostingh GJ, Pozgajova M, Ludwig RJ, Krahn T, Boehncke WH, Nieswandt B, Schon MP. Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. Haematologica 2007;92:502–512. Epub 2007/ 05/10.
   PubMed Web of Science ®Google Scholar
• Alfonso F, Angiolillo DJ. Targeting P-selectin during coronary interventions: the elusive link between inflammation and platelets to prevent myocardial damage editorials published in the journal of the American college of cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American COLLEGE OF CARDIOLOGY. J Am Coll Cardiol 2013;61:2056–2059.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Abt M, Ciorciaro C, Kling D, Jamois C, Schick E, Solier C, Benghozi R, Gaudreault J. First-in-man study with inclacumab, a human monoclonal antibody against P-selectin. J Cardiovasc Pharmacol 2015;65:611–619. Epub 2015/ 02/26.
   PubMed Web of Science ®Google Scholar
• Kling D, Stucki C, Kronenberg S, Tuerck D, Rheaume E, Tardif JC, Gaudreault J, Schmitt C. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab–preclinical and clinical studies. Thromb Res 2013;131:401–410. Epub 2013/ 03/26.
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Tanguay J-F, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for Non–ST-segment elevation myocardial infarction: results of the SELECT-ACS Trial. J Am Coll Cardiol 2013;61:2048–2055.
   PubMed Web of Science ®Google Scholar
• Stocker JW, Mandarino D, Kawar Z, Alvarez R, Falconer D, Rollins SA, Rother RP. Placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose, healthy subject study of intravenous-administered SelG1, a humanized Anti-P-selectin antibody in development for sickle cell disease. Blood 2013;122:970.
   Google Scholar
• Kutlar A, Kanter J, Liles DK, Alvarez OA, Cancado RD, Friedrisch JR, Knight-Madden JM, Bruederle A, Shi M, Zhu Z, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am J Hematol 2019;94:55–61. Epub 2018/ 10/09.
   PubMed Web of Science ®Google Scholar
• Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr., Hennan JK, Kaila N, Debernardo S, et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther 2008;324:497–506. Epub 2007/ 11/21.
   PubMed Web of Science ®Google Scholar
• Myers DD Jr., Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G, Meier TR, Hawley AE, Schaub RG, Wakefield TW. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 2006;44:625–632. Epub 2006/ 09/05.
   PubMed Web of Science ®Google Scholar
• Japp AG, Chelliah R, Tattersall L, Lang NN, Meng X, Weisel K, Katz A, Burt D, Fox KA, Feuerstein GZ, et al. Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc 2013;2:e006007. Epub 2013/ 03/26.
   PubMed Web of Science ®Google Scholar
• Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002;88:488–494.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004;43:1982–1988.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012;13:195–203. Epub 2012/ 02/24.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005;11:507–514. Epub 2005/ 04/19.
   PubMed Web of Science ®Google Scholar
• Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. J Biol Chem 2009;284:33763–33772. Epub 2009/ 08/21.
   PubMed Web of Science ®Google Scholar
• Garcia A, Kim S, Bhavaraju K, Schoenwaelder Simone M, Kunapuli Satya P. Role of phosphoinositide 3-kinase β in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 2010;429:369–377.
   PubMed Web of Science ®Google Scholar
• Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, Vanhaesebroeck B, Payrastre B, Gratacap MP. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010;115:2008–2013. Epub 2010/ 01/13.
   PubMed Web of Science ®Google Scholar
• Nylander S, Kull B, Bjorkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skarby T, Inghardt T, Fjellstrom O, et al. Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost 2012;10:2127–2136. Epub 2012/ 08/22.
   PubMed Web of Science ®Google Scholar
• Nylander S, Wågberg F, Andersson M, Skärby T, Gustafsson D. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. J Thrombosis Haemostasis 2015;13:1494–1502.
   PubMed Web of Science ®Google Scholar
• Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195–233. Epub 2013/ 12/05.
   PubMed Web of Science ®Google Scholar
• Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011;72:634–646.
   PubMed Web of Science ®Google Scholar
• Hidaka H, Asano T. Human blood platelet 3ʹ: 5ʹ-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta 1976;429:485–497. Epub 1976/ 04/08.
   PubMed Web of Science ®Google Scholar
• Grant PG, Colman RW. [72] Purification of cAMP phosphodiesterase from platelets. In: Methods in Enzymology.Academic Press; 1988. p. 772–777.
   Google Scholar
• Tilley DG, Maurice DH. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 2002;62:497–506. Epub 2002/ 08/16.
   PubMed Web of Science ®Google Scholar
• Movsesian M, Ahmad F, Hirsch E. Functions of PDE3 isoforms in cardiac muscle. J Cardiovasc Dev Dis 2018;5:10.
   Web of Science ®Google Scholar
• Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3c–12c. Epub 1999/ 03/17.
   PubMed Web of Science ®Google Scholar
• Manns JM, Brenna KJ, Colman RW, Sheth SB. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Thromb Haemost 2002;87:873–879. Epub 2002/ 06/01.
   PubMed Web of Science ®Google Scholar
• Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, Wada H, Kimura Y, Ikeda Y, Shiku H, Nishikawa M. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci 1997;61:PL383–PL389.
   Web of Science ®Google Scholar
• Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung 1987;37:563–566.
   PubMed Web of Science ®Google Scholar
• Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 2019;18:539–548. Epub 2019/ 05/28.
   PubMed Web of Science ®Google Scholar
• Li J, Xiang X, Xu Z. Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB). Biotechnol Appl Biochem 2019;66:555–563. Epub 2019/ 04/18.
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Lin F-Y, Lin Y-W, Cheng S-M, Lin R-H, Chuang C-L, Sheu J-S, Chen S-M, Chang -C-C, Tsai C-S. DAPT plus cilostazol is better than traditional DAPT or aspirin plus ticagrelor as elective PCI for intermediate-to-highly complex cases: prospective, randomized, PRU-based study in Taiwan. Am J Cardiovasc Drugs 2019;19:75–86.
   PubMed Web of Science ®Google Scholar
• Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733–739. Epub 2009/ 04/01.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Y, Tang Y, Huang X, Xie Y. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin 2014;30:37–49. Epub 2013/ 10/03.
   PubMed Web of Science ®Google Scholar
• Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010;159:284–291.e281. Epub 2010/ 02/16.
   PubMed Web of Science ®Google Scholar
• Beppu S, Nakajima Y, Shibasaki M, Kageyama K, Mizobe T, Shime N, Matsuda N. Phosphodiesterase 3 inhibition reduces platelet activation and monocyte tissue factor expression in knee arthroplasty patients. Anesthesiology 2009;111:1227–1237. Epub 2009/ 11/26.
   PubMed Web of Science ®Google Scholar
• Wesley MC, McGowan FX, Castro RA, Dissanayake S, Zurakowski D, Dinardo JA. The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg 2009;108:1425–1429. Epub 2009/ 04/18.
   PubMed Web of Science ®Google Scholar
• Kikura M, Sato S. Effects of preemptive therapy with milrinone or amrinone on perioperative platelet function and haemostasis in patients undergoing coronary bypass grafting. Platelets 2003;14:277–282. Epub 2003/ 08/29.
   PubMed Web of Science ®Google Scholar
• Douglas JS Jr., Holmes DR Jr., Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826–2832. Epub 2005/ 10/26.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, Bhatt DL. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart 2014;1:e000068.
   PubMedGoogle Scholar